Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | — | 1 | — | — | 1 |
Diabetic cardiomyopathies | D058065 | EFO_1001458 | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Covid-19 | D000086382 | — | U07.1 | — | 1 | — | — | — | 1 |
Carcinoma | D002277 | — | C80.0 | 1 | 1 | — | — | — | 1 |
Inflammatory breast neoplasms | D058922 | — | — | 1 | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Oxidative stress | D018384 | EFO_1001905 | — | 1 | — | — | — | 1 | 2 |
Drug common name | Caficrestat |
INN | caficrestat |
Description | Caficrestat is a small molecule pharmaceutical. It is currently being investigated in clinical studies. |
Classification | Small molecule |
Drug class | enzyme inhibitors: aldose-reductase inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | O=C(O)Cc1nn(Cc2nc3cc(C(F)(F)F)ccc3s2)c(=O)c2nccnc12 |
PDB | — |
CAS-ID | 1355612-71-3 |
RxCUI | — |
ChEMBL ID | CHEMBL4297455 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | E8I3O45DDU (ChemIDplus, GSRS) |